Globalagliatin: Difference between revisions
Content deleted Content added
←Created page with ''''Globalagliatin''' (SY-004) is a glucokinase activator developed by Yabao Pharmaceutical Group for type 2 diabetes.<ref>{{cite journal |last1=Zhao |first1=Yuqing |last2=Xie |first2=Lijun |last3=Zhang |first3=Hongwen |last4=Zhou |first4=Sufeng |last5=Liu |first5=Yun |last6=Chen |first6=Juan |last7=Wang |first7=Lu |last8=Wang |first8=Libin |last9=Zhuo |first9=Lang |last10=Wang |first10=Yarong |last11=Ou |first11=Ning |last12=Shao |first12=Feng |title=T...' |
(No difference)
|
Revision as of 05:58, 1 December 2023
Globalagliatin (SY-004) is a glucokinase activator developed by Yabao Pharmaceutical Group for type 2 diabetes.[1][2][3]
References
- ^ Zhao, Yuqing; Xie, Lijun; Zhang, Hongwen; Zhou, Sufeng; Liu, Yun; Chen, Juan; Wang, Lu; Wang, Libin; Zhuo, Lang; Wang, Yarong; Ou, Ning; Shao, Feng (February 2022). "Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study". Clinical Therapeutics. 44 (2): 269–281. doi:10.1016/j.clinthera.2021.12.009.
- ^ Zheng, Shuai; Shao, Feng; Ding, Yu; Fu, Zhenzhen; Fu, Qi; Ding, Sijia; Xie, Lijun; Chen, Juan; Zhou, Sufeng; Zhang, Hongwen; Zhou, Hongwen; Chen, Yang; Sun, Caixia; Zhu, Jing; Zheng, Xuqin; Yang, Tao (December 2020). "Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study". Clinical Drug Investigation. 40 (12): 1155–1166. doi:10.1007/s40261-020-00971-x.
- ^ Yang, Wenjia; Wu, Han; Cai, Xiaoling; Lin, Chu; Jiao, Ruoyang; Ji, Linong (8 May 2023). "Evaluation of efficacy and safety of glucokinase activators—a systematic review and meta-analysis". Frontiers in Endocrinology. 14. doi:10.3389/fendo.2023.1175198.
{{cite journal}}: CS1 maint: unflagged free DOI (link)